TITLE

PAUL VARNELL

AUTHOR(S)
Varnell, Paul
PUB. DATE
May 2001
SOURCE
Bay Windows;5/10/2001, pN.PAG
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
Provides information on how much it costs to manufacture generic or knock-off versions of AIDS antivirals that are for sale in underdeveloped countries. Cost of a year supply of GlaxoSmithKline's Combivir, a combination of AZT and 3TC; Price of the generic version of Combivir offered by Cipla Ltd.; Purpose of drug patents.
ACCESSION #
15802963

 

Related Articles

  • Generic antibiotics in Japan. Fujimura, Shigeru; Watanabe, Akira // Journal of Infection & Chemotherapy (Springer Science & Business;Aug2012, Vol. 18 Issue 4, p421 

    Generic drugs have been used extensively in many developed countries, although their use in Japan has been limited. Generic drugs reduce drug expenses and thereby national medical expenditure. Because generic drugs provide advantages for both public administration and consumers, it is expected...

  • Competition body rules that drug companies "abused" their position. Sidley, Pat // BMJ: British Medical Journal (International Edition);10/25/2003, Vol. 327 Issue 7421, p946 

    Discusses a ruling by South Africa's competition regulatory body in favor of AIDS activists who want South African makers of generic drugs to be able to produce cheap copies of antiretroviral drugs which are under patent protection. Abuse of market position by pharmaceutical companies,...

  • Bush declines to support drug companies' line on AIDS profits. Dickson, David // Nature;3/1/2001, Vol. 410 Issue 6824, p3 

    Reports that United States President George W. Bush's administration has agreed to take a liberal attitude toward the efforts of developing countries to produce generic AIDS treatments. Response to the announcement by AIDS activists and public-interest groups; Opinion that publicly funded...

  • Pricing Regime.  // Canada Pharma & Healthcare Report;Q4 2011, Issue 4, p21 

    The article discusses the pricing and reimbursement regime in Canada covering patented and generic drugs. The approval of patented drug prices is a long and complex process involving 19 bodies led by the government's Common Drug Review and Patented Medicines Review Board. The latter regulates...

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • News in brief….  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p11 

    The article presents information on a study conducted in The Netherlands which examined the effect of drug patent expiry for enalapril on the sale of generic drugs. The researchers found that after the patent expiry, the sale of generic drugs in the country increased.

  • Patent-extending tactics trouble generics makers. Chater, Amanda // Drug Store News;8/28/2006, Vol. 28 Issue 10, p56 

    The article provides an overview of the performance of the generic drug industry in the United States. It describes the impact of the expirations of branded drugs' patents on the industry. Generic drug sales increased by 20.6 percent to $22.3 billion in 2005. It is estimated that $64 billion...

  • Authorized generics debate continues.  // Drug Store News;8/28/2006, Vol. 28 Issue 10, p60 

    The article reports on the controversy over the issue of authorized generic drugs in the United States. According to the article, authorized generic drugs are those that are made by a branded drug company launched to coincide with the loss of a patent of one of their own products. To manufacture...

  • CNS News Round-Up.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p2 

    Reports on developments related to the pharmaceutical industry as of October 2003. Move of Novartis AG to license Cytos Biotechnology's Immunodrugs against Alzheimer's disease; Approval from the U.S. Food and Drug Administration granted to GlaxoSmithKline PLC to expand the indications of Paxil...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics